The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet
Not Applicable
Recruiting
- Conditions
- Patients on maintenance hemodialysis treated with cinacalcet for secondary hyperparathyroidism
- Registration Number
- JPRN-UMIN000028041
- Lead Sponsor
- Matsunami general hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Nothing
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iPTH, Ca, P, side effect, dosage of etelcalcetide and vitamin D
- Secondary Outcome Measures
Name Time Method Bone mineral density (0, 6, 12 months) BAP, TRACP (0, 6, 12 months) ABI and PWV, IMT (carotid ultrasound) ACI and ACAI (abdominal CT) (0, 12 months)